



## Samsca<sup>®</sup> (tolvaptan) – First-time generic

- On May 20, 2020, Alkem/Ascend and [Apotex launched AB-rated](#) generic versions of Otsuka's [Samsca \(tolvaptan\)](#) 30 mg tablets.
- Samsca is approved for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure and syndrome of inappropriate antidiuretic hormone.
- Tolvaptan is also available as brand 15 mg tablets (Samsca) and brand 15 mg and 30 mg tablets ([Jynarque<sup>®</sup>](#)).
  - Jynarque is approved to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
- Samsca carries a boxed warning to initiate and re-initiate in a hospital and monitor serum sodium; and not for use for autosomal dominant polycystic kidney disease.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.